| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
48 |
| Employees |
259 |
| Revenues (TTM) (Millions $) |
214 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
5 |
Business Description
Aerie Pharmaceuticals Inc is a pharmaceutical company that specializes in developing and commercializing treatments for various eye diseases.
The company is headquartered in Durham, North Carolina, and was founded in 2005.
Aerie Pharmaceuticals' lead product is Rhopressa, a once-daily eye drop used to treat intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The company also has another product called Rocklatan, which is a combination of Rhopressa and latanoprost, another medication that lowers IOP.
The company's products work by targeting the trabecular meshwork, which is responsible for draining the fluid that circulates in the eye.
By increasing the fluid outflow, Rhopressa and Rocklatan reduce IOP and help prevent damage to the optic nerve, which can lead to vision loss.
Aerie Pharmaceuticals has conducted several clinical trials to test the safety and efficacy of its products.
The company's research and development efforts are focused on advancing new treatments for glaucoma, as well as other eye diseases such as age-related macular degeneration and diabetic macular edema.
As of 2021, Aerie Pharmaceuticals operates in the United States and has partnerships with several global pharmaceutical companies.
The company employs more than 300 people and is committed to providing innovative eye care solutions to patients around the world.
Company Address: 4301 Emperor Boulevard, Suite 400 Durham 27703 NC
Company Phone Number: 237-5300 Stock Exchange / Ticker: NASDAQ AERI
|
%
4.81% 